GlassScriptPhysician profile
Samuel A Schadt
NPI 1437710076
$4,652.63
in general payments reported to CMS, 2019-2025
13 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,701 · 2022: $858 · 2023: $814 · 2024: $740 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,300.08 | 2021 | |
| Alcon Vision LLC | $1,050.89 | 2021-2025 | Clareon, Centurion, Unity |
| Bausch & Lomb Americas INC. | $903.91 | 2022-2025 | Envista Envy, Envista Mx60 Iol, Envista Aspire Iol |
| Sight Sciences, INC. | $311.27 | 2022 | |
| Rayner Intraocular Lenses Limited | $272.69 | 2024-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Horizon Therapeutics Plc | $214.64 | 2021 | |
| Abbvie INC. | $180.85 | 2022-2023 | Ozurdex |
| Ocular Therapeutix, INC. | $121.88 | 2024-2025 | Dextenza |
| Rxsight INC | $100.00 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $92.31 | 2024-2025 | |
| Oyster Point Pharma, INC. | $58.11 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $25.59 | 2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $20.41 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Schadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.